Focused On-demand Library for FYN-binding protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O15117

UPID:

FYB1_HUMAN

Alternative names:

Adhesion and degranulation promoting adaptor protein; FYB-120/130; FYN-T-binding protein; SLAP-130; SLP-76-associated phosphoprotein

Alternative UPACC:

O15117; A8K2Y8; B4DLN2; E9PBV9; O00359; Q9NZI9

Background:

FYN-binding protein 1, known by alternative names such as Adhesion and degranulation promoting adaptor protein and SLAP-130, plays a crucial role in T-cell signaling, actin cytoskeleton remodeling, and platelet activation. It acts as an adapter in the FYN and LCP2 signaling cascades and modulates IL2 expression, essential for immune response regulation.

Therapeutic significance:

Linked to Thrombocytopenia 3, a disorder characterized by a reduced platelet count leading to increased bleeding risks, FYN-binding protein 1's involvement in platelet activation and immune signaling pathways presents a promising target for therapeutic intervention in hematologic disorders.